Trials / Completed
CompletedNCT00166322
Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Ludwig-Maximilians - University of Munich · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging technique under amphetamine challenge.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | IBZM-SPECT (bolus and constant infusion paradigm) | single IBZM-SPECT assessment at study inclusion |
Timeline
- Start date
- 2004-01-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2005-09-14
- Last updated
- 2008-05-07
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00166322. Inclusion in this directory is not an endorsement.